Back to Search
Start Over
OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
- Source :
- British Journal of Cancer, Paediatrics Publications
- Publication Year :
- 2014
-
Abstract
- Background: Treatment of advanced and metastatic colorectal cancer with irinotecan is hampered by severe toxicities. The active metabolite of irinotecan, SN-38, is a known substrate of drug-metabolising enzymes, including UGT1A1, as well as OATP and ABC drug transporters. Methods: Blood samples (n=127) and tumour tissue (n=30) were obtained from advanced cancer patients treated with irinotecan-based regimens for pharmacogenetic and drug level analysis and transporter expression. Clinical variables, toxicity, and outcomes data were collected. Results: SLCO1B1 521C was significantly associated with increased SN-38 exposure (P
- Subjects :
- Adult
Male
Cancer Research
Disease free survival
medicine.medical_treatment
Organic Anion Transporters
colorectal cancer
Pharmacology
Organic Anion Transporters, Sodium-Independent
Irinotecan
Polymorphism, Single Nucleotide
SN-38
Disease-Free Survival
Solute Carrier Organic Anion Transporter Family Member 1B3
Medicine
Humans
heterocyclic compounds
neoplasms
Aged
Aged, 80 and over
Chemotherapy
business.industry
Liver-Specific Organic Anion Transporter 1
OATP1B3
OATP1B1
Middle Aged
Antineoplastic Agents, Phytogenic
digestive system diseases
Multidrug Resistance-Associated Protein 2
stomatognathic diseases
Oncology
Toxicity
Cancer research
Camptothecin
Female
Multidrug Resistance-Associated Proteins
business
Colorectal Neoplasms
Translational Therapeutics
therapeutics
medicine.drug
Subjects
Details
- ISSN :
- 15321827
- Volume :
- 112
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- British journal of cancer
- Accession number :
- edsair.doi.dedup.....fd3e5ba3bfd26b02c02c321c238cbc0e